iCAD Inc
ICAD

$1.28

3.03%

Market Cap: 34M

About: icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.

Employees: 69

Healthcare Surgical & Medical Instruments & Apparatus

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

0% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 14

3.25% less ownership

Funds ownership: 26.21% [Q4 2023] → 22.96% (-3.25%) [Q1 2024]

4% less funds holding

Funds holding: 52 [Q4 2023] → 50 (-2) [Q1 2024]

20% less first-time investments, than exits

New positions opened: 8 | Existing positions closed: 10

20% less capital invested

Capital invested by funds: $12.2M [Q4 2023] → $9.73M (-$2.49M) [Q1 2024]

52% less call options, than puts

Call options by funds: $33K | Put options by funds: $69K

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for ICAD.

See Analyst Rankings

Financial journalist opinion

iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024

Newly Launched ProFound Cloud Delivers Radiologists Cost-Effective, Secure, and Scalable Access to iCAD's Breast Health Suite of AI Solutions Newly Launched ProFound Cloud Delivers Radiologists Cost-Effective, Secure, and Scalable Access to iCAD's Breast Health Suite of AI Solutions

iCAD to Highlight Promising Research on Potential of its AI Algorithm to More Accurately Identify and Personalize Breast Cancer Risk at SIIM 2024

iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference

NASHUA, N.H., June 04, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, announced today the Company will present at the MedInvest MedTech, AI & Digital Healthcare Conference on June 11-12, 2024 in San Francisco, CA. Dana Brown, Chief Executive Officer, and Eric Lonnqvist, Chief Financial Officer, of iCAD, Inc., will participate in one-on-one meetings with investors at the event.

iCAD to Participate in the MedInvest MedTech, AI & Digital Health Conference

3 Top Small-Cap Growth Opportunities in the AI Era

It's certainly a very good time to be in the AI business. After all, the technology has been getting huge amounts of positive publicity since December 2022, and it's being viewed as a powerful, helpful tool for humans.

3 Top Small-Cap Growth Opportunities in the AI Era

iCAD, Inc. (ICAD) Q1 2024 Earnings Call Transcript

iCAD, Inc. (NASDAQ:ICAD ) Q1 2024 Results Conference Call May 15, 2024 8:30 AM ET Company Participants Jeremiah Bennett - Vice President, Marketing Dana Brown - President and Chief Executive Officer Eric Lonnqvist - Chief Financial Officer Conference Call Participants Per Ostlund - Craig-Hallum Yale Jen - Laidlaw & Company Operator Good day, ladies and gentlemen, and welcome to the iCAD Incorporated First Quarter 2024 Earnings Call. At this time, all participants have been placed on a listen-only mode, and floor will be open for questions and comments following the presentation.

iCAD, Inc. (ICAD) Q1 2024 Earnings Call Transcript

iCAD Reports Financial Results for First Quarter Ended March 31, 2024

NASHUA, N.H., May 15, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) a global leader on a mission to create a world where cancer can't hide by providing clinically proven AI-powered breast health solutions, today reported its financial and operating results for the three months ended March 31, 2024.

iCAD Reports Financial Results for First Quarter Ended March 31, 2024

UPDATE - iCAD to Report First Quarter 2024 Financial Results on May 15, 2024

NASHUA, N.H., May 08, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 8:30 AM Eastern Time on Wednesday, May 15, 2024.

UPDATE - iCAD to Report First Quarter 2024 Financial Results on May 15, 2024

iCAD to Report First Quarter 2024 Financial Results on May 15, 2024

NASHUA, N.H., May 02, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will release financial results for the first quarter ended March 31, 2024, pre-market and host a conference call at 10:00 AM Eastern Time on Wednesday, May 15, 2024.

iCAD to Report First Quarter 2024 Financial Results on May 15, 2024

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

NASHUA, N.H., April 11, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced today it will showcase its ProFound Breast Health Suite of AI solutions, including the newly released ProFound Cloud, powered by Google Cloud and Google Health AI architecture, while also highlighting its recently announced partnership with Densitas®, a global leader in AI solutions for breast cancer screening, at the Society for Breast Imaging (SBI) annual symposium, April 11-14 in Montreal, Canada. In addition, iCAD will feature its recent release of the ProFound Detection Workstation features for streamlined mammogram interpretations in booth #512.

iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

NASHUA, N.H. and HALIFAX, Nova Scotia, April 09, 2024 (GLOBE NEWSWIRE) -- iCAD, Inc . (NASDAQ: ICAD), a global leader in clinically proven AI-powered cancer detection solutions, announced a strategic partnership with Densitas, Inc., a global leader in operational AI solutions for breast cancer screening. The partnership enables breast imaging centers and radiologists to provide end-to-end breast health care that ensures every aspect of a woman's breast health journey is addressed, starting from the first step of quality screening mammograms and extending through breast cancer detection, breast density assessment, and a comprehensive evaluation of breast cancer risk.

iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation

iCAD's ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

Study confirms iCAD's Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms Study confirms iCAD's Breast Arterial Calcification AI Algorithm successfully detects calcification of breast vessels, an indicator of cardiovascular disease, from mammograms

iCAD's ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting

See News Rankings